Evidence map›Paper›PMID 41117873›Full record

ArticleJournal of clinical immunology2025

Type I IFNs Decrease SARS-CoV-2 Replication in Human Cardiomyocytes and Increase Cytokine Production in Macrophages.

Verónica Durán, Eirini Nikolouli, Shambhabi Chatterjee, Bibiana Costa, Andreas Pavlou, Annett Ziegler, Jennifer Becker, Kira Baumann, Matthias Bruhn, Kathrin Haake and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Verónica Durán *Institute for Experimental Infection Research, TWINCORE, Centre for Experimental and Clinical Infection Research, a joint venture between the Helmholtz Centre for Infection Research [HZI], Braunschweig, and the Hannover Medical School [MHH], 30625, Hannover, Germany.
Eirini Nikolouli *Department for Pediatric Pneumology, Allergology and Neonatology, Hannover Medical School [MHH], 30625, Hannover, Germany.
Shambhabi Chatterjee *Institute of Molecular and Translational Therapeutic Strategies, Hannover Medical School [MHH], 30625, Hannover, Germany.
Bibiana CostaInstitute for Experimental Infection Research, TWINCORE, Centre for Experimental and Clinical Infection Research, a joint venture between the Helmholtz Centre for Infection Research [HZI], Braunschweig, and the Hannover Medical School [MHH], 30625, Hannover, Germany.
Andreas PavlouInstitute for Experimental Infection Research, TWINCORE, Centre for Experimental and Clinical Infection Research, a joint venture between the Helmholtz Centre for Infection Research [HZI], Braunschweig, and the Hannover Medical School [MHH], 30625, Hannover, Germany.
Annett ZieglerInstitute for Experimental Infection Research, TWINCORE, Centre for Experimental and Clinical Infection Research, a joint venture between the Helmholtz Centre for Infection Research [HZI], Braunschweig, and the Hannover Medical School [MHH], 30625, Hannover, Germany.
Jennifer BeckerInstitute for Experimental Infection Research, TWINCORE, Centre for Experimental and Clinical Infection Research, a joint venture between the Helmholtz Centre for Infection Research [HZI], Braunschweig, and the Hannover Medical School [MHH], 30625, Hannover, Germany.
Kira BaumannInstitute for Experimental Infection Research, TWINCORE, Centre for Experimental and Clinical Infection Research, a joint venture between the Helmholtz Centre for Infection Research [HZI], Braunschweig, and the Hannover Medical School [MHH], 30625, Hannover, Germany.
Matthias BruhnInstitute for Experimental Infection Research, TWINCORE, Centre for Experimental and Clinical Infection Research, a joint venture between the Helmholtz Centre for Infection Research [HZI], Braunschweig, and the Hannover Medical School [MHH], 30625, Hannover, Germany.
Kathrin HaakeInstitute of Experimental Hematology, Hannover Medical School [MHH], 30625, Hannover, Germany.
Anna Rafiei HashtchinInstitute of Experimental Hematology, Hannover Medical School [MHH], 30625, Hannover, Germany.
Ingrid GenschDepartment for Pediatric Pneumology, Allergology and Neonatology, Hannover Medical School [MHH], 30625, Hannover, Germany.
Andrea KorteInstitute of Molecular and Translational Therapeutic Strategies, Hannover Medical School [MHH], 30625, Hannover, Germany.
Yvonne Lisa BehrensDepartment of Human Genetics, Hannover Medical School [MHH], 30625, Hannover, Germany.
Shen-Ying ZhangLaboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Paris, France.
Jean-Laurent CasanovaLaboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Paris, France.
Christian BärInstitute of Molecular and Translational Therapeutic Strategies, Hannover Medical School [MHH], 30625, Hannover, Germany.
Nico Lachmann *Department for Pediatric Pneumology, Allergology and Neonatology, Hannover Medical School [MHH], 30625, Hannover, Germany.
Thomas Thum *Institute of Molecular and Translational Therapeutic Strategies, Hannover Medical School [MHH], 30625, Hannover, Germany.
Ulrich Kalinke *Institute for Experimental Infection Research, TWINCORE, Centre for Experimental and Clinical Infection Research, a joint venture between the Helmholtz Centre for Infection Research [HZI], Braunschweig, and the Hannover Medical School [MHH], 30625, Hannover, Germany. Ulrich.Kalinke@twincore.de.ORCID 0000-0003-0503-9564

Funding

Developing, Demonstrating, and Disseminating Innovative Programs to Achieve Translational SuccessUL1TR001866 · NCATS · ROCKEFELLER UNIVERSITY · PI COLLER, BARRY, KRUEGER, JAMES G · 2016 to 2025
$40.6M
Monogenic basis of resistance to SARS-CoV2 and predisposition to severe COVID-19R01AI088364 · NIAID · UT SOUTHWESTERN MEDICAL CENTER · PI Jean-Laurent Casanova, Shen-Ying Zhang · 2010 to 2026
$8.7M
Inborn errors of immunity in patients with life-threatening COVID-19R01AI163029 · NIAID · ROCKEFELLER UNIVERSITY · PI CASANOVA, JEAN-LAURENT, ZHANG, QIAN · 2021 to 2025
$3.7M
NCATS NIH HHS UL1 TR001866NIAID NIH HHS R01 AI088364NIAID NIH HHS R01 AI163029
6 · The paper itself

Abstract

The cellular basis of COVID-19 severity in patients with deficiencies in type I IFN immunity remains unclear. In this study, we differentiated cardiomyocytes and macrophages from IFNAR1 competent (IFNAR1

Indexed as

COVID-19CytokinesInterferon Type IMacrophagesMyocytes, CardiacSARS-CoV-2Virus ReplicationAngiotensin-Converting Enzyme 2Cells, CulturedHumansInduced Pluripotent Stem CellsInterferon-alphaReceptor, Interferon alpha-betaACE2 protein, humanAngiotensin-Converting Enzyme 2CytokinesIFNAR1 protein, humanInterferon-alphaInterferon Type IReceptor, Interferon alpha-beta

Identifiers

PMID41117873
PMCPMC12540622

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.